The government of Canada has authorized a startup to export psychedelics to Australia for medical use. Optimi Health Corp. is now tasked with shipping pills containing psilocybin, an extract from magic mushrooms, and MDMA, as sanctioned by the health department.
The rising demand is not limited to local magic mushrooms Ontario. Other countries are following Canada’s lead and beginning to investigate and allow the use of serotogenic compounds for medicinal purposes.
You can confidently buy psychedelics online in Canada and tap into your inherent potential through trustworthy sources.
[toc]Main Points:
- Optimi Health, a Vancouver-based startup, has received a drug establishment license to export magic mushroom pills to Australia.
- In Australia, licensed psychiatrists are allowed to use magic mushrooms in treating chronic depression.
- The treatment consists of three sessions over a period of five to eight weeks, with each session lasting around eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and gain early market entry advantage.
Seven companies have exported psilocybin, MDMA, or both, but only for clinical trial purposes. A representative from Canada’s health department couldn’t confirm if these exports were for regular patient use and declined to name the companies due to security reasons.
This milestone places Optimi among a small group of international suppliers, with the current market focusing more on clinical rather than recreational use.
What’s in the Pill?
Although the company hasn’t identified the exact mushroom strain used in the pill, it does work with several varieties, including Albino Penis Envy and others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, for cultivating, testing, and extracting from its psychedelic mushrooms. This quaint town of approximately 3,000 residents is situated a three-hour drive to the east of Vancouver.
The Connection Between Australia and Psychedelic Mushrooms
It’s projected that 1 in every 5 Australians between the ages of 16 and 85 may experience mental illness. PTSD (post-traumatic stress disorder) is expected to impact 11% of Australians at some point, while anxiety disorders are common among 17% of the population.
There’s a vast spectrum of mental health treatment methods, but not all are effective for everyone. For individuals unresponsive to certain treatments, finding an effective approach can be difficult, consequently increasing their susceptibility.
Understanding the Process
Australia is a trailblazer in the application of psilocybin, authorizing licensed psychiatrists to use this regulated substance in the treatment of PTSD and depression resistant to traditional therapies.
In a groundbreaking move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and shrooms for therapeutic use. The TGA asserted that these substances are safe when used in a medically controlled setting for patients grappling with severe mental conditions.
This advancement has revolutionized the perspective of many mental health professionals and researchers. The administration of these substances will be strictly monitored; it’s not about simply taking a pill and departing.
The treatment regimen typically consists of three sessions over a span of five to eight weeks. Each session lasts around eight hours, with the therapist accompanying the patient throughout.
Canada’s Role in Psilocybin Research
Canada has evolved as a significant center for psilocybin research, greatly expanding our understanding of this compound. Health Canada, in collaboration with various institutions, is leading the investigation into the therapeutic potential of psilocybin in treating diverse mental health disorders.
Research institutions are no longer required to label these substances as illegal or rely on unauthorized dispensaries or mushroom stores. The government now permits certain institutions to grow shrooms for research objectives.
The increased availability of substances previously deemed detrimental allows researchers to delve deeper into their potential advantages for numerous individuals.
A Recurring Trend
Back in the 1950s, pioneers in the field identified its potential in addressing mental health problems and substance abuse, including alcoholism. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were the frontrunners of this early research conducted at the Saskatchewan Mental Hospital in Weyburn. Under the leadership of then-premier Tommy Douglas, the institution saw considerable progress, as the medical community was given significant freedom to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer began investigations into the use of LSD, mescaline, and peyote as possible alternatives to harsh practices like electroshock and lobotomy. Their investigations took unforeseen turns, leading them to advocate that doctors, nurses, and support staff experiment with these substances.
Research Institutes of Health in Canada
Under the umbrella of the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Main Investigator | Budget for Project |
| A randomized controlled trial | Psychological distress in terminal cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms underpinning psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
The funds allocated to this research will contribute to a more extensive understanding of the advantages of controlled substances. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Canadian Government, has made this possible.
Further Psychedelic Research
In Vancouver, psychiatrists have initiated a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment includes three eight-hour sessions with MDMA, scheduled a month apart, and nine 90-minute sessions without the drug. This trial is considered historically important as it marks the first clinical test of an illegal It’s been over forty years since a psychedelic substance was analyzed and studied.
Deciphering Psilocybin
Psilocybin is a psychedelic compound that naturally occurs in certain types of mushrooms. Upon consumption, it transforms into psilocin. This psilocin activates the serotonin 5-HT2a receptors found on the brain’s cortical pyramidal cells, which serve as the primary processing centers.
Authorities are studying this substance for its potential ability to aid with depression, anxiety, addiction, and distress during the end of life by promoting introspection and spiritual enlightenment.
Why is it Effective in Treating Depression, PTSD, and More?
The active component interacts with various brain regions, making it beneficial for a range of mental disorders. Numerous patients in Canada and Australia have received this treatment, and the reported results are promising, with minor side effects like temporary anxiety or increased blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound partially stimulates serotonin receptors, particularly the 5-HT2A subtype, playing an essential role in emotional processing and mood management.
- Default Mode Network (DMN) Regulation: It reduces DMN activity, promoting introspection, minimizing inflexible thought patterns, and enhancing emotional flexibility.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant properties of the substance stem from its effects on the prefrontal and limbic brain regions, including the amygdala. In instances of depression, people generally show reduced responsiveness to emotional stimuli. The compound magnifies the response to positive emotional stimuli in the right amygdala and diminishes or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Emotional States: Stimulates a sense of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic journey may empower individuals to safely address and process deep-seated emotions, traumatic memories, or existential fears in a supportive setting.
- Spiritual and Existential Realizations: Studies from Johns Hopkins University and Imperial College London suggests that it can result in enduring positive changes, including better overall well-being, heightened life satisfaction, and spiritual growth.
What Can Be Found at Your Local Magic Mushroom Store?
Interested in how this substance might impact your mental health? You can explore magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, stimulates creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and enhances overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Promotes clarity, creativity, and concentration. Contains a potent mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
International Recognition of Psilocybin
Canada is not the sole country endorsing the use of magic mushrooms for mental health conditions. Countries like Australia are also accepting the use of these hallucinogens to treat conditions such as depression and PTSD. They are procuring top-quality psychedelic capsules from trustworthy sources. Under proper supervision, patients can significantly improve their quality of life. Strongest Shroom Strain Canada, a magic mushroom retailer, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA compare?
Both psilocybin and MDMA have therapeutic potential by enhancing mental well-being. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD therapy. It demonstrates potential in improving emotional processing and
Despite being classified as a controlled substance, this treatment has shown promising therapeutic effects.
Is this treatment option accessible to all Australians?
No. In Australia, an assessment must first be conducted to verify an individual’s eligibility for using the substance. This assessment takes into account factors such as existing heart conditions, a history of psychosis, and others. Only patients who have not benefited from conventional treatments for disorders such as depression, anxiety, or PTSD can access this treatment.
What impact does Canada’s export of mushrooms have?
Canada is positioning itself as a major player in the psychedelics market, mirroring its approach towards cannabis. This could encourage more companies to produce high-quality products. As a result, Canada could be a leading force in the hallucinogens market, bolster its economy, and make treatments more accessible for other countries. Furthermore, it would prevent other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Articles You Might Find Intriguing:
